Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies

Authors:

Abstract
No abstract available
Funding Information
  • Otsuka Pharmaceutical Co, Ltd, Japan
  • Public Health Service Grant
  • National Cancer Institute (5U24-CA076518)
  • National Heart, Lung and Blood Institute
  • National Institute of Allergy and Infectious Diseases
  • NHLBI (5U10HL069294)
  • NCI
  • Health Resources and Services Administration (HHSH250201200016C)
  • Office of Naval Research (N00014-13-1-0039, N00014-14-1-0028)
  • Alexion
  • *Amgen, Inc
  • Anonymous donation to the Medical College of Wisconsin
  • Be The Match Foundation
  • *Bristol Myers Squibb Oncology
  • *Celgene Corp
  • *Chimerix, Inc
  • Fred Hutchinson Cancer Center
  • Gamida Cell Ltd
  • Genentech, Inc
  • Genzyme Corp
  • *Gilead Sciences, Inc
  • Health Research, Inc.
  • Roswell Park Comprehensive Cancer Center
  • HistoGenetics, Inc
  • Incyte Corp
  • *Jazz Pharmaceuticals, Inc
  • Jeff Gordon Children's Foundation
  • Leukemia & Lymphoma Society
  • Medical College of Wisconsin
  • Merck & Co, Inc
  • Mesoblast
  • *Millennium: The Takeda Oncology Co
  • *Miltenyi Biotec, Inc
  • National Marrow Donor Program
  • Neovii Biotech NA, Inc
  • Novartis Pharmaceuticals Corp
  • Onyx Pharmaceuticals
  • Optum Healthcare Solutions, Inc
  • Otsuka America Pharmaceutical, Inc
  • Otsuka Pharmaceutical Co, Ltd–Japan
  • Oxford Immunotec
  • PerkinElmer, Inc
  • Pharmacyclics
  • *Sanofi US
  • Seattle Genetics
  • Sigma-Tau Pharmaceuticals
  • *Spectrum Pharmaceuticals, Inc
  • St. Baldrick's Foundation
  • *Sunesis Pharmaceuticals, Inc
  • Swedish Orphan Biovitrum, Inc
  • Telomere Diagnostics, Inc
  • TerumoBCT
  • THERAKOS, Inc
  • University of Minnesota
  • *Wellpoint, Inc.

This publication has 37 references indexed in Scilit: